Soligenix’ LPM uttered stupefy conveyance technology receives Hong Kong copyright
Soligenix, Inc. (OTC Announcement Lodge: SNGX) (Soligenix or the Business, a late-stage biotechnology body, announced today that it has received a Hong Kong evident which addresses its Lipid Polymer Micelle (LPM™) technology as a remedy for the improved word-of-mouth deliverance of drugs. The issued Hong Kong trade name, HK 1071054, entitled "Stabilized Converse Micelle Compositions and Uses Thereof" covers lipid structures Disaffirm micelles) that further the intestinal absorption of peptides and other finely tuned drugs that cannot in another situation be dedicated orally.
"The issuance of the Hong Kong permit also in behalf of LPM™ to boot demonstrates the plaything of this poison enunciation set-up and the preclinical results distinctly display that it is a competitive modus operandi as regards enunciated conveyance of drugs, primarily those biotechnology products derived from mock peptide chemistry or recombinant DNA," said Christopher J. Schaber, PhD, Soligenix President and CEO. "We also hold that the LPM™ procedure at ones desire be pertinent to a big-hearted figure of water-soluble drugs including peptides that are below par permeable, resulting in increased forbearing compliance and safety."
The issuance of this blatant in Hong Kong follows the issuance of the still and all blatant in Europe in 2009.
COMMENCEMENT Soligenix, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
